Journal of Experimental & Clinical Cancer Research

CORRECTION

Open Access

Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

Yulin Peng[1†], Yan Wang[1†], Ning Tang[1,3†], Dongdong Sun[1], Yulong Lan[1], Zhenlong Yu[1,2], Xinyu Zhao[1], Lei Feng[1,2], Baojing Zhang[1], Lingling Jin[1], Fabiao Yu[2], Xiaochi Ma[1,2*] and Chuanzhu Lv[2*]

Correction: ***J Exp Clin Cancer Res*** **37, 248 (2018)**
https://doi.org/10.1186/s13046-018-0926-9

Following publication of the original article [1], errors were found in Figs. 6 and 8. The band of β-actin in Fig. 6B (Basal) and the band of CD31 in Fig. 8F were mistakenly uploaded.

The corrected figures are provided below:

The corrections do not affect the overall result, discussion, or conclusion of the article.

†Yulin Peng, Yan Wang and Ning Tang contributed equally to this work.

The original article can be found online at https://doi.org/10.1186/s13046-018-0926-9.

*Correspondence:
Xiaochi Ma
maxc1978@163.com
Chuanzhu Lv
lvchuanzhu677@126.com
[1] Institute of Integrative Medicine, College of Pharmacy, College of Basic Medical Science, Dalian Medical University, Dalian 116044, China
[2] Emergency Department, The Second Affiliated Hospital of Hainan Medical University, Haikou 571199, China
[3] Department of Integrative Medicine, Liaoning University of Traditional Chinese Medicine Xinglin College, Shenyang 110167, China



Fig. 6 Effect of Andro on VEGF-induced angiogenesis. **a** HUVECs were exposed to Andro at the indicated doses, and viability was measured by CCK-8 assay. Data were represented as percentage of vehicle-treated control. **b** The expression level of COX-2 protein was analyzed by Western blot HUVECs treated with the indicated doses of Andro for 48 h, with or without VEGF induction. **c-d** Effects of Andro on tube formation on Matrigel c at 6 h (Original magnifcation, 50×), and sprouting from modifed human endothelial cell spheroids **d** at 24 h (Original magnifcation, 200×). Experiments were performed with or without VEGF and indicated Andro doses. (##$p < 0.01$, VEGF-treated group vs. Solvent; *$P < 0.05$, **$P < 0.01$, Andro treatment vs vehicle control groups)



Fig. 8 Effect of Andro on tumor growth and tumor angiogenesis in a breast cancer mouse model. An orthotopic mouse model of human breast cancer MDA-MB-231 cells was used to evaluate the anti-tumor effect of Andro. The tumor pictures (**a**), tumor volumes (**b**) and total weights (**c**) were measured. d The expressions of COX-2 and CD31 in tumor samples were analyzed by immunohistochemistry and cofocol immunofluorescence, respectively. **e** The quantitative analysis of relative COX-2 expression and microvessel number were also performed. **f** The expression of COX-2 and CD31 proteins in tumor tissues was analyzed by Western blot. Data were represented as the mean ± S.D. (*$P < 0.05$, **$P < 0.01$, Andro treatment vs vehicle control groups, $N = 5$ mice/group. Magnification, 200×)

Published online: 16 September 2023

Reference

1. Peng Y, Wang Y, Tang N, et al. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res. 2018;37:248. https://doi.org/10.1186/s13046-018-0926-9.